JP7312106B2 - 新しいｐｄｌ２化合物 - Google Patents

新しいｐｄｌ２化合物 Download PDF

Info

Publication number
JP7312106B2
JP7312106B2 JP2019522726A JP2019522726A JP7312106B2 JP 7312106 B2 JP7312106 B2 JP 7312106B2 JP 2019522726 A JP2019522726 A JP 2019522726A JP 2019522726 A JP2019522726 A JP 2019522726A JP 7312106 B2 JP7312106 B2 JP 7312106B2
Authority
JP
Japan
Prior art keywords
peptide fragment
peptide
seq
amino acids
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500171A (ja
JP2020500171A5 (enExample
Inventor
ハルド アンデルセン，マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2020500171A publication Critical patent/JP2020500171A/ja
Publication of JP2020500171A5 publication Critical patent/JP2020500171A5/ja
Priority to JP2023077867A priority Critical patent/JP2023109840A/ja
Application granted granted Critical
Publication of JP7312106B2 publication Critical patent/JP7312106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019522726A 2016-10-27 2017-10-13 新しいｐｄｌ２化合物 Active JP7312106B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077867A JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16195949.9 2016-10-27
EP16195949 2016-10-27
PCT/EP2017/076179 WO2018077629A1 (en) 2016-10-27 2017-10-13 New pdl2 compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077867A Division JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Publications (3)

Publication Number Publication Date
JP2020500171A JP2020500171A (ja) 2020-01-09
JP2020500171A5 JP2020500171A5 (enExample) 2020-11-12
JP7312106B2 true JP7312106B2 (ja) 2023-07-20

Family

ID=57211335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522726A Active JP7312106B2 (ja) 2016-10-27 2017-10-13 新しいｐｄｌ２化合物
JP2023077867A Pending JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077867A Pending JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Country Status (5)

Country Link
US (4) US20200024324A1 (enExample)
EP (1) EP3532487A1 (enExample)
JP (2) JP7312106B2 (enExample)
CN (1) CN109890838A (enExample)
WO (1) WO2018077629A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858642B2 (en) * 2016-10-07 2020-12-08 Io Biotech Aps Immunogenic arginase peptides
WO2018077629A1 (en) 2016-10-27 2018-05-03 Herlev Hospital New pdl2 compounds
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502414A (ja) 2000-06-30 2004-01-29 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
JP2012500847A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストの組成物および使用方法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP2514762B1 (en) * 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
EP2195347A1 (en) * 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CA2735006A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
US20170044268A1 (en) * 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
EP3283508B1 (en) * 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
WO2018077629A1 (en) 2016-10-27 2018-05-03 Herlev Hospital New pdl2 compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502414A (ja) 2000-06-30 2004-01-29 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
JP2012500847A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストの組成物および使用方法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Front.Immunol.,2017,8:292,p.1-16

Also Published As

Publication number Publication date
US20250236658A1 (en) 2025-07-24
US20230227529A1 (en) 2023-07-20
US20200024324A1 (en) 2020-01-23
US12215135B2 (en) 2025-02-04
WO2018077629A1 (en) 2018-05-03
CN109890838A (zh) 2019-06-14
JP2020500171A (ja) 2020-01-09
EP3532487A1 (en) 2019-09-04
US20200392202A1 (en) 2020-12-17
JP2023109840A (ja) 2023-08-08
US11447537B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
JP5502823B2 (ja) Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
EP3263585B1 (en) Foxm1 peptide and medicinal agent comprising the same
JP2023109840A (ja) 新しいｐｄｌ２化合物
US20250230218A1 (en) Pdl1 peptides for use in cancer vaccines
US20240167013A1 (en) Immunogenic arginase peptides
Nakajima et al. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration
CN113966342A (zh) TGF-β疫苗
JP2022507373A (ja) 免疫原性アルギナーゼ２ポリペプチド
CN112771159A (zh) 精氨酸酶1多肽
HK40012895A (en) Immunogenic arginase peptides
HK1244819B (en) Foxm1 peptide and medicinal agent comprising the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230707

R150 Certificate of patent or registration of utility model

Ref document number: 7312106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150